Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry
Viktoria Papp(Copenhagen University Hospital), Melinda Magyari(University of Copenhagen), Svend Sparre Geertsen, Zsolt Illés(Universität Hamburg), Peter Vestergaard Rasmussen(Aarhus University Hospital), Volkert Siersma(University of Copenhagen), J. Zs. Mezei(University of Southern Denmark), Homayoun Roshanisefat(University of Southern Denmark), Claudia Hilt(Aalborg University Hospital), Stephan Bramow(Copenhagen University Hospital), Tobias Sejbæk(University of Southern Denmark), Arkadiusz Wêglewski(Rigshospitalet), Janneke van Wingerden(Sanofi (Netherlands)), Finn Sellebjerg(Danish Multiple Sclerosis Center), Mathias Due Buron(Rigshospitalet), Matthias Kant(Sygehus Sønderjylland)
Cited by 20
Related Papers
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
|Science|2019|1.4k
EFNS guidelines on diagnosis and management of neuromyelitis optica
|European Journal of Neurology|2010|469
Worldwide Incidence and Prevalence of Neuromyelitis Optica
|Neurology|2020|303
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
|Journal of Neurology Neurosurgery & Psychiatry|2016|297
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
|CNS Drugs|2014|293